Incyte's Zynyz EU Approval Adds Niche Oncology Growth, But Fails to Shift Core Patent Cliff Narrative

What happened

Incyte has received European Commission approval for Zynyz in combination with chemotherapy for advanced anal cancer, marking the first systemic treatment for this indication. According to the DeepValue report, Zynyz is part of Incyte's broader oncology portfolio aimed at diversifying revenue ahead of Jakafi's 2028 patent cliff. However, Zynyz contributes minimally to current revenues compared to Jakafi's $2.26 billion in the first nine months of 2025 and Opzelura's $471 million, as highlighted in the report. The approval is a positive regulatory milestone but does not materially alter the company's dependence on Jakafi or the fragile economics of Opzelura, which face payer pressure and CMS line-extension risks. Thus, while this expands Zynyz's label, it remains a small piece in Incyte's challenging transition story, keeping the investment thesis focused on larger catalysts like Opzelura growth and tafasitamab approvals.

Implication

For investors, this approval adds a new indication for Zynyz, potentially boosting oncology sales modestly in the EU. However, given the small market size of advanced anal cancer, the financial impact is likely limited and insufficient to offset Jakafi's future decline. The DeepValue report emphasizes that Incyte's valuation hinges on Opzelura sustaining >20% growth and successful tafasitamab launches, not on niche expansions like this. Critical risks such as CMS classification of Opzelura and generic competition for Jakafi remain unchanged, preserving the asymmetric downside highlighted in the report. Therefore, investors should view this news as a minor positive that doesn't warrant a change in position sizing or conviction, reinforcing the need to monitor larger proof points over the next 6-12 months.

Thesis delta

This news does not significantly alter the investment thesis, as Zynyz's contribution is too small to affect the diversification bridge away from Jakafi. The core thesis remains that Incyte must execute on Opzelura and tafasitamab to de-risk the 2028 patent cliff, and this approval adds negligible upside. No shift in the thesis; maintain focus on the key drivers and risks outlined in the DeepValue report.